IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
BRENTWOOD, Tenn., Sept. 09, 2022 (GLOBE NEWSWIRE) — IMAC Holdings, Inc. (Nasdaq:BACK) (“IMAC” or “the Company”), today announces it has completed the third cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease.
Related news for (BACK)
- Double Digit Stock Gainers with News: SLXN, SYTA, TRIB, and BACK
- Top Trending Stocks Under $15 Being Traded Today: SYTA, BACK, YIBO, TRIB, ZKIN
- IMAC Holdings Forms Ignite Proteomics to Enhance Personalized Therapy for Cancer Patients
- IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies
- 24/7 Market News Snapshot 27 January, 2025 – IMAC Holdings, Inc. Common Stock (NASDAQ:BACK)